Beta Bionics, Inc. (BBNX) AI Stock Analysis

Beta Bionics, Inc., incorporated in 2015 and headquartered in Irvine, California, is a commercial-stage medical device company. The company designs, develops, and commercializes solutions to improve the health and quality of life of insulin-requiring people with diabetes. Its primary commercial product is the iLet Bionic Pancreas, an automated insulin delivery device for treating type 1 diabetes in adults and children six years of age and older. Beta Bionics is also developing the Patch Pump, a tubeless insulin pump; the Bihormonal iLet, which delivers both insulin and glucagon; and an iLet platform for insulin-dependent type-2 diabetes. It maintains partnerships with Xeris Pharmaceuticals, Inc. and Abbott Diabetes Care Inc.

Beta Bionics generated revenue of $179,000 in FY2022, which increased to $12.0M in FY2023, $65.1M in FY2024, and $100.3M in FY2025, resulting in a 3-year revenue CAGR of 724.3%. Annual revenue expanded 53.9% in FY2025, with a gross margin of 55.4% and an operating margin of -71.5%. Net losses widened to -$73.2M in FY2025 from -$54.8M in FY2024 and -$44.1M in FY2023, generating an EPS of -$1.83 in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue grew 37.8% year-over-year. Over the trailing twelve months, revenue reached $119.0M with a profit margin of -61.3%.

As of June 30, 2026, Beta Bionics held $180.5M in cash and short-term investments alongside $6.5M in total debt, resulting in net cash of $174.0M. The company reported shareholders' equity of $256.4M, total assets of $292.4M, a current ratio of 8.88, and a debt-to-equity ratio of 0.03. In FY2025, operating cash flow stood at -$50.9M and free cash flow was -$56.2M, with capital expenditures totaling $5.3M.

Beta Bionics closed at $16.35 on October 16, 2026, representing a market capitalization of $882.0M and an enterprise value of $1.02B. The stock trades at a price-to-sales multiple of 7.4x and an EV-to-revenue multiple of 8.6x, compared to a median price-to-sales multiple of 4.1x for its US-listed Healthcare peers. Its price-to-book multiple is 4.7x. Over the past year, the stock declined 20.7%, trailing the 16.8% return of the S&P 500 (SPY). Year-to-date, the stock fell 46.3% and trades 7.8% above its 200-day average.

Beta Bionics has analyst ratings consisting of 9 Strong Buy, 2 Buy, and 4 Hold recommendations. The mean price target is $24.24, which is 48.3% above the October 16, 2026 close of $16.35. The company beat EPS estimates in each of the last 4 quarters. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $124.4M and EPS of -$1.88. For the following fiscal year, 3 analysts project revenue of $182.6M and EPS of -$2.16. The next earnings date is October 27, 2026.

This page is an AI-written research summary of Beta Bionics, Inc. (BBNX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BBNX income statement, BBNX balance sheet, BBNX key metrics, BBNX analyst forecast, BBNX chart. See the BBNX stock overview for the latest quote and news.